Fig 1.
Treatment scheme of all patients (A) and an example of the treatment for a patient receiving prostate radiotherapy (B).
Table 1.
Characteristics of the entire patient cohort and comparisons between patients with and without prostate radiotherapy (PRT).
Fig 2.
Extent and site of radiotherapy for patients receiving prostate radiotherapy (PRT) or palliative radiotherapy (RT).
Non spine*: site of bone metastasis except in the pelvic bone and spine (C-T-L spine).Pelvis**: bone metastasis, including metastasis to the pubic, ischial, and iliac bones and the sacrum and proximal femur.
Fig 3.
(A) Kaplan–Meier curves for overall survival (OS) and biochemical failure-free survival (BCFFS) of patients receiving prostate radiotherapy (PRT) and those who did not. OS (p = 0.004) and BCFFS (p = 0.002) were better in PRT patients than in non-PRT patients. (B) Kaplan-Meier curves for overall survival (OS) and biochemical failure-free survival (BCFFS) of non-prostate radiotherapy (PRT) patients with and without palliative radiotherapy (RT).
In the non-PRT group, OS and BCFFS did not differ significantly between patients receiving palliative RT and those receiving non-palliative RT.
Table 2.
Univariate and multivariate analyses of overall survival.